Journal article
Gene–environment interactions involving functional variants: Results from the Breast Cancer Association Consortium
M Barrdahl, A Rudolph, JL Hopper, MC Southey, A Broeks, PA Fasching, MW Beckmann, M Gago-Dominguez, JE Castelao, P Guénel, T Truong, SE Bojesen, SM Gapstur, MM Gaudet, H Brenner, V Arndt, H Brauch, U Hamann, A Mannermaa, D Lambrechts Show all
International Journal of Cancer | WILEY | Published : 2017
DOI: 10.1002/ijc.30859
Abstract
Investigating the most likely causal variants identified by fine-mapping analyses may improve the power to detect gene–environment interactions. We assessed the interplay between 70 single nucleotide polymorphisms identified by genetic fine-scale mapping of susceptibility loci and 11 epidemiological breast cancer risk factors in relation to breast cancer. Analyses were conducted on up to 58,573 subjects (26,968 cases and 31,605 controls) from the Breast Cancer Association Consortium, in one of the largest studies of its kind. Analyses were carried out separately for estrogen receptor (ER) positive (ER+) and ER negative (ER–) disease. The Bayesian False Discovery Probability (BFDP) was comput..
View full abstractRelated Projects (2)
Grants
Awarded by Agence Nationale de la Recherche
Funding Acknowledgements
Grant sponsor: Cancer Research UK; Grant number: C1287/A16563, C1287/A10118, C1287/A10710, C12292/A11174, C1281/A12014, C5047/A8384, C5047/A15007, C5047/A10692, C8197/A16565; Grant sponsor: European Union's Horizon 2020 Research and Innovation Programme; Grant number: 634935, 633784; Grant sponsor: European Community's Seventh Framework Programme; Grant number: 223175 (HEALTHF2-2009-223175); Grant sponsor: National Institutes of Health; Grant number: CA128978; Grant sponsor: Post-Cancer GWAS initiative; Grant number: 1U19 CA148537, 1U19 CA148065, 1U19 CA148112; Grant sponsor: Department of Defence; Grant number: W81XWH-10-1-0341; Grant sponsor: Canadian Institutes of Health Research (CIHR); Grant number: CRN-87521; Grant sponsor: Komen Foundation for the Cure; Grant sponsor: Breast Cancer Research Foundation; Grant sponsor: Ovarian Cancer Research Fund; Grant sponsor United States National Cancer Institute, National Institutes of Health (NIH); Grant number: RFA-CA-06-503; Grant sponsor: Breast Cancer Family Registry (BCFR), Cancer Care Ontario; Grant number: U01 CA69467; Grant sponsor: Cancer Prevention Institute of California; Grant number: U01 CA69417; Grant sponsor: University of Melbourne; Grant number: U01 CA69638; Grant sponsor: National Cancer Institute; Grant number: UM1 CA164920; Grant sponsor: National Health and Medical Research Council of Australia; Grant sponsor: New South Wales Cancer Council; Grant sponsor: Victorian Health Promotion Foundation; Grant sponsor: Victorian Breast Cancer Research Consortium; Grant sponsor: Dutch Cancer Society; Grant number: NKI 2007-3839; 2009-4363; Grant sponsor: Dutch Government; Grant number: NWO 184.021. 007; Grant sponsor: Dutch National Genomics Initiative; Grant sponsor: ELAN-Fond; Grant sponsor: Accion Estrategica de Salud del Institute de Salud Carlos III; Grant number: FIS PI12/02125, PI13/01136; Grant sponsor: KAU; Grant number: 1-117-1434-HiCi; Grant sponsor: Botin Foundation's Fund; Grant sponsor: Programa Grupos Emergentes, Cancer Genetics Unit, CHUVI Vigo Hospital, Institute de Investigacion Sanitaria Galicia Sur (IISGS), Institute de Salud Carlos III, Spain; Grant sponsor: Conselleria de Industria Programa Sectorial de Investigacion Aplicada, PEME vertical bar DEI vertical bar Suma del Plan Gallego de Investigacion, Desarrollo c Innovation Tecnologica de la Conselleria de Industria de la Xunta de Galicia, Spain; Grant number: 10CSA012E; Grant sponsor: Fomento de la Investigation Clinica Indcpendiente, Ministerio de Sanidad, Servicios Sociales e Igualdad, Spain; Grant number: EC11-192; Grant sponsor: Grant FEDER-Innterconecta, Ministerio de Economia y Competitividad, Xunta de Galicia, Spain; Grant sponsor: Fondation de France; Grant sponsor: Institut National du Cancer (INCa); Grant sponsor: Ligue Nationale contre le Cancer; Grant sponsor: Ligue contre le Cancer Grand Ouest; Grant sponsor: Agence Nationale de Securite Sanitaire (ANSES); Grant sponsor: Agent Nationale de la Recherche (ANR); Grant sponsor: Chief Physician Johan Boserup and Lise Boserup Fund; Grant sponsor: Danish Medical Research Council; Grant sponsor: Herlev Hospital; Grant sponsor: American Cancer Society; Grant sponsor: Baden Wurttemberg Ministry of Science, Research and Arts; Grant sponsor: German Cancer Aid (Deutsche Krcbshilfe); Grant sponsor: Federal Ministry of Education and Research (BMBF), Germany; Grant number: 01KW9975/5, 01KW9976/8, 01KW9977/0, 01KW0114; Grant sponsor: Robert Bosch Foundation, Stuttgart; Grant sponsor: Deutsches Krebsforschungszentrum (DKFZ), Heidelberg; Grant sponsor: Institute for Prevention and Occupational Medicine of the German Social Accident Insurance; Grant sponsor: Institute of the Ruhr University Bochum (IPA), Bochum; Grant sponsor: Department of Internal Medicine, Evangelische Kliniken Bonn gGmbH, Johanniter Krankenhaus, Bonn, Germany; Grant sponsor: Government Funding (EVO) of Kuopio University Hospital; Grant sponsor: Cancer Fund of North Savo; Grant sponsor: Finnish Cancer Organizations; Grant sponsor: University of Eastern Finland; Grant sponsor: Stichting tegen Kanker; Grant number: 232-2008, 196-2010; Grant sponsor: FWO; Grant number: KULPFV/10/016-SymBioSysII; Grant sponsor: KULPFV; Grant number: 70-2892-BR I, 106332, 108253, 108419, 110826, 110828; Grant sponsor: Hamburg Cancer Society; Grant sponsor: NIH Specialized Program of Research Excellence (SPORE) in Breast Cancer; Grant number: CA116201; Grant sponsor: David F. and Margaret T. ; Grant sponsor: Grohnc Family Foundation; Grant sponsor: VicHealth; Grant sponsor: Cancer Council Victoria; Grant sponsor: NHMRC; Grant number: 209057, 251553, 504711; Grant sponsor: Quebec Breast Cancer Foundation; Grant sponsor: CIHR Team in Familial Risks of Breast Cancer; Grant sponsor: Ministry of Economic Development, Innovation and Export Trade; Grant number: # PSR-S11R1-701; Grant sponsor: Intramural Research Funds, National Cancer Institute, Department of Health and Human Services, USA; Grant sponsor: Marit and Hans Rausings Initiative Against Breast Cancer; Grant sponsor: Cancer Risk Prediction Center CRisP; Grant sponsor: Linnaeus Centre; Grant sponsor: Swedish Research Council; Grant number: 70867902; Grant sponsor: Agency for Science, Technology and Research of Singapore (A*STAR); Grant sponsor US National Institute of Health (NIH); Grant sponsor: Susan G. Komen Breast Cancer Foundation; Grant sponsor: Yorkshire Cancer Research; Grant number: S295, S299, S305PA; Grant sponsor: Sheffield Experimental Cancer Medicine Centre; Grant sponsor: UK National Institute for Health Research Biomedical Research Centre, University of Cambridge; Grant sponsor: Cancer Research UK; Grant sponsor: Breast Cancer Now; Grant sponsor: Institute of Cancer Research (ICR), London; Grant sponsor: Cancer Care Ontario; Grant number: U01 CA69467; Grant sponsor: National Cancer Institute; Grant number: UM1 CA164920; Grant sponsor: Accion Estrategica de Salud del Instituto de Salud Carlos III; Grant number: EIS PI12/02125, PI13/01136